The Medicines and Healthcare Products Regulatory Agency (MHRA) has for the first time approved the use of a dual (ICS/beta-agonist) combination treatment to be prescribed as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an alternative to its current use as a preventer therapy sitting later in traditional treatment pathways.

At PCRS, we know how busy primary care is and realise that introducing a new treatment choice means change and that changes take time, can use up scarce resource, and can feel like a threat. In this resource, we will show you how to take small steps to try out this new treatment pathway on a limited patient group, using a real-world test of change in a GP practice and show the key steps to help make implementation a success